Form 4: Spyre Therapeutics CEO Sells 15,000 Shares Under 10b5-1 Plan

Spyre Therapeutics CEO Cameron Turtle sold 15,000 shares of common stock for approximately $435,463.50 under a pre-arranged 10b5-1 trading plan.

Summary

• Cameron Turtle, Chief Executive Officer and Director of Spyre Therapeutics, Inc. (SYRE), reported the sale of 15,000 shares of the company's common stock.
• The transactions occurred on December 1, 2025, and were executed pursuant to a Rule 10b5-1 trading plan adopted on June 20, 2025.
• The first sale involved 10,995 shares at a weighted average price of $28.73 per share, with prices ranging from $28.45 to $29.44.
• The second sale involved 4,005 shares at a weighted average price of $29.83 per share, with prices ranging from $29.47 to $30.43.
• The total proceeds from these sales amounted to approximately $435,463.50.
• Following these transactions, Cameron Turtle beneficially owns 686,907 shares of common stock.
• This remaining ownership includes 174,228 shares of common stock that vest in monthly installments over approximately one year, subject to the reporting person's continuing service.

Sentiment

Score: 4

Explanation: The sale by a CEO and Director, while under a 10b5-1 plan, can still be perceived negatively by the market as it reduces insider ownership. However, the pre-planned nature mitigates some of the immediate negative sentiment compared to an unplanned, opportunistic sale.

Positives

• The sales were conducted under a pre-arranged Rule 10b5-1 trading plan, which indicates a planned and systematic approach to personal financial management rather than a reactive decision based on new, undisclosed information.

Negatives

• An insider sale by the CEO and a Director, even if pre-planned, can be perceived negatively by some investors, potentially signaling a lack of confidence or a desire to diversify personal holdings away from the company's stock.

Risks

• Potential for negative investor sentiment due to insider selling, which could lead to short-term downward pressure on the company's stock price.

Future Outlook

The filing does not provide specific forward-looking statements or guidance beyond the details of the stock transactions.

Industry Context

This Form 4 filing reports an individual insider transaction and does not provide broader industry context or trends. Insider sales are a common occurrence across all industries, often for personal financial planning or diversification, especially when executed under a Rule 10b5-1 plan.

Stakeholder Impact

• Shareholders: May interpret the insider sale as a negative signal, potentially leading to decreased confidence or selling pressure on the stock, despite the 10b5-1 plan context.
• Employees: No direct impact mentioned, but general market sentiment could indirectly affect employee morale if the stock price reacts negatively.

Next Steps

• The remaining 174,228 shares of common stock held by the reporting person are subject to monthly vesting over approximately one year, contingent on continued service to the company.

Key Dates

Recommendation

While the CEO's sale of 15,000 shares might raise questions, it was conducted under a pre-arranged 10b5-1 plan, which suggests a planned diversification or liquidity event rather than a reaction to new negative information. The remaining beneficial ownership of 686,907 shares, including a significant portion subject to future vesting, indicates continued alignment with shareholder interests. Without additional financial or operational updates, a 'hold' recommendation is appropriate, advising investors to monitor future company performance and insider activity.

Keywords

Spyre Therapeutics, SYRE, Cameron Turtle, Insider Trading, Form 4, Stock Sale, 10b5-1 Plan, CEO, Director, Equity Sales